% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • mauihope1969 mauihope1969 Mar 10, 2014 12:06 PM Flag

    Why a buy?


    I'm a buyer today. Cantor's sell is right, right, right if your looking at this year's numbers only.
    I have no doubt Adcetris will be approved frontline NHL and cd30 B-Cell. That is 10-20 times current approved indications. They now have just about a 2000 patient population which generates $140 ml. Do the math.
    CD-30 cancer is larger than just NHL.
    My peak Adceetris sales estimate is $1.5bil - $2bil. and a $100-$150 2016 share price.
    While looking for stocks which can rise if the market turns down this fits the bill. No debt. No need to raise capital in an offering. Revenue growth which will go exponential.
    SGEN is a no-brainer buy.
    This is just my opinion. I'm long. Do your own research. This is not a recommendation to buy.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
43.77-0.72(-1.62%)Jul 26 4:00 PMEDT